Table 1.
Physicochemical characteristics of organic nanoparticles.
| Organic NPs | REF | Functional group | Diameter (nm) | ζ - potential (mV) | Tested uropathogens | Activity | |
|---|---|---|---|---|---|---|---|
| Aminocellulose nanospheres | (Macedo et al., 2017) | Primary amine | 268 ± 7 | 103 ± 2 | E. coli | Antibiofilm | |
| Aminocellulose nanospheres/hyaluronic acid construct | (Francesko et al., 2016) | Hyaluronic acid | 268 ± 7 | 103 ± 2 | P. aeruginosa | Antibiofilm | |
| Glycerol monolaurate nanocapsules | (Lopes et al., 2019) | – | 190.7 ± 2 | -23.3 ± 3 | P. aeruginosa | Antibiofilm | |
| Chlorhexidine-loaded poly(ε-caprolactone) nanospheres | (Phuengkham and Nasongkla, 2015) | poly(ε-caprolactone) | 198.8 ± 6.9 | – | S. aureus, S. epidermidis and E. coli | Antibacterial | |
| Chlorhexidine-loaded poly(ε-caprolactone) nanospheres | (Srisang and Nasongkla, 2019) | poly(ε-caprolactone) | 152 ± 37 | 40.21 ± 1.08 | E. coli, S. aureus, and C. albicans | Antibacterial | |
| Polyurethane chlorhexidine nanocomposites | (Francesko et al., 2016) | – | – | – | S. epidermidis | Antibacterial | |
| Kanamycin-chitosan nanoparticles | (Venkat Kumar et al., 2016) | NA | 225 | 36 | E. coli and P. mirabilis | Antibacterial | |
| Antibiofilm | |||||||
| Chlorin e6 encapsulated charge-conversion polymeric nanoparticles | (Lui et al., 2015) | poly (β-amino ester)s | 33.5 ± 4.5 | -6 | S. aureus and E. coli | Antibacterial | |
| chitosan-coated poly(lactide-co-glycolide) nanoparticles loaded with amphotericin B | (Ludwig et al., 2018) | poly(lactide-co-glycolide) | 459 ± 22 | 18 ± 3.5 | Candida sp. | Antifungal | |
| Nano catechin | (Yoon et al., 2011) | – | 100 – 200 | – | E. coli | Antibacterial | |
| Polyphenol 60 and curcumin nanoemulsion based gel (intravaginal) | (Kaur et al., 2017a) | – | 211.2 | -32.7 | UPEC | Antibacterial | |
| polyphenol 60 + cranberry nanoemulsion based gel (intravaginal) | (Kaur et al., 2017b) | – | 58 | -16 | E. coli | Antibacterial | |
| Polyphenol 60 and ciprofloxacin | (Atinderpal et al., 2018) | – | 151.7 | 55.3 | E. coli, K. pneumoniae, P. mirabilis, C. amalonatus and C. diversus | Antibacterial | |
| Bilayer nanocapsules containing lutA antigen (vaccine) | (Crecente-Campo et al., 2018) | – | 200 ± 2 | 42 ± 4 | E. coli, K. pneumoniae, P. mirabilis, C. amalonatus and C. diversus | Vaccine |